AQR Capital Management
CLYM

AQR Capital Management’s Climb Bio CLYM Stock Holding History

AQR Capital Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-28,890
Closed -$35.8K – 3628
2025
Q2 		$35.8K Buy
28,890
+7,082
+32% +$8.81K ﹤0.01% 3255
2025
Q1 		$26.6K Sell
21,808
-3,373
-13% -$5.47K ﹤0.01% 3116
2024
Q4 		$45.3K Buy
25,181
+14,811
+143% +$53.6K ﹤0.01% 2815
2024
Q3 		$52.8K Buy
+10,370
New +$73.4K ﹤0.01% 2702

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AQR Capital Management's CLYM Position: Q3 2025 in Review

AQR Capital Management sold out of Climb Bio (CLYM) in Q3 2025, closing a stake of 28,890 shares — an estimated $35.8K sold.

AQR Capital Management first reported a position in CLYM in Q3 2024 and held it in 4 quarters. The position peaked at $52.8K in Q3 2024. 68 funds tracked by Wall St. Rank hold CLYM as of Q3 2025.

  • AQR Capital Management reported no remaining Climb Bio position as of Q3 2025 after selling out during the quarter.
  • AQR Capital Management sold 28,890 Climb Bio shares in Q3 2025, an estimated $35.8K.
  • AQR Capital Management first reported a position in Climb Bio in Q3 2024 and held it in 4 quarters.
  • AQR Capital Management's Climb Bio position peaked at $52.8K in Q3 2024.
  • 68 funds tracked by Wall St. Rank held Climb Bio as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.